Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 9 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Royalty Pharma PLC | RPRX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 27.98 | 08:54:37 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 27.98 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 3 | 9 | - | 25.92 - 35.95 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 09:06:31 | 3 | $ 28.14 | USD |
Royalty Pharma PLC Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 16.72B | 597.43M | - | 2.35B | 1.13B | 1.90 | 14.73 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Royalty Pharma News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RPRX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 27.54 | 28.40 | 27.21 | 27.91 | 2,769,682 | 0.44 | 1.60% |
| 1 Month | 30.55 | 30.80 | 27.21 | 28.66 | 2,657,555 | -2.57 | -8.41% |
| 3 Months | 28.46 | 31.655 | 27.21 | 29.59 | 2,857,101 | -0.48 | -1.69% |
| 6 Months | 27.36 | 31.655 | 26.07 | 28.75 | 2,581,900 | 0.62 | 2.27% |
| 1 Year | 35.82 | 35.95 | 25.92 | 29.62 | 2,436,102 | -7.84 | -21.89% |
| 3 Years | 44.00 | 47.10 | 25.92 | 36.12 | 2,117,675 | -16.02 | -36.41% |
| 5 Years | 45.90 | 57.50 | 25.92 | 38.26 | 2,139,566 | -17.92 | -39.04% |
Royalty Pharma Description
| Royalty Pharma PLC is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The company assembles a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's therapies, which includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Johnson & Johnson's Tremfya, Gilead's Trodelvy, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates. |
